Clinical Trials Logo

Clinical Trial Summary

This is an open observational extended follow-up study of patients originally randomized into TOOKAD® Soluble VTP therapy or active surveillance (control group). Additional 60-month follow-up study


Clinical Trial Description

This is an open observational extended follow-up study of patients originally randomized into TOOKAD® Soluble VTP therapy or active surveillance (control group). No intervention or further intervention with TOOKAD® Soluble is mandated in this additional 60-month follow-up study where patients in the original TOOKAD® Soluble group and active surveillance (control) group are both managed by their physician as appropriate to their condition using any treatment available following a 'local standard of care' principle from the end of the trial (M24) up to the end of follow-up (M84). Management decisions are entirely left to clinicians and their patients in this pragmatic extension of the trial (no criteria imposed) where standard of care that reflects clinical practice within each centre is applied. All patients originally randomised in study CLIN1001 PCM301, whether allocated to the TOOKAD® Soluble VTP arm (n=206) or Active surveillance arm (n=207 and who did not withdraw their consent will be included in this extension study. This extension study consists of 2 different follow-up: - a follow-up of patients via investigators - and a follow-up via interviews directly with patients ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04017325
Study type Observational
Source Steba Biotech S.A.
Contact
Status Completed
Phase
Start date March 17, 2016
Completion date June 3, 2020

See also
  Status Clinical Trial Phase
Completed NCT03653819 - High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs N/A
Withdrawn NCT05191017 - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Phase 1/Phase 2
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Not yet recruiting NCT06363266 - A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers N/A
Active, not recruiting NCT02003924 - Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Phase 3
Completed NCT00643617 - CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry N/A
Completed NCT00844792 - Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer Phase 2
Completed NCT01303705 - Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Phase 1
Completed NCT02578940 - Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer Phase 3
Completed NCT04057859 - PCa Patients Managed With ADT to Examine the Effect of Nutritional Guidance and Aerobic/Resistance Fitness Training
Completed NCT00564928 - A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer Phase 2
Completed NCT02958787 - Vessel Sparing Prostate Radiation Therapy Phase 2
Completed NCT01897207 - Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer Phase 1/Phase 2
Recruiting NCT05241236 - MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer
Active, not recruiting NCT03939689 - Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone Phase 2
Completed NCT02274350 - The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects N/A
Completed NCT00744549 - Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance Phase 2
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02212548 - Prostate-Rectal Separation With PEG Hydrogel and Its Effect on Decreasing Rectal Dose N/A
Active, not recruiting NCT03238170 - MR-simulation in Radiotherapy for Prostate Cancer N/A